≡ Menu

Chantix (varenicline): Label Change – Risk of Certain Cardiovascular Adverse Events

A Drug & Medical Device Recall And/Or Safety Alert Has Been Issued: Chantix (varenicline): Label Change – Risk of Certain Cardiovascular Adverse Events. According to the Food & Drug Administration FDA’s MedWatch:

Results of a randomized, double-blind, placebo-controlled clinical trial of 700 smokers reviewed.

For more information on the drug or medical device recall or safety alert, read the Food & Drug Administration’s FDA’s drug or medical device recall or safety alert: Chantix (varenicline): Label Change – Risk of Certain Cardiovascular Adverse Events.

To report an adverse reaction, problem or other issue with a drug or medical device, submit a drug or medical device complaint to the government at fda.gov or MedWatch.

If you have thoughts on the drug or medical device recall or safety alert, share your drug or medical device recall or safety alert comments below.

{ 0 comments… add one }

Leave a Comment